Enhanced Expression of RAGE AXIS Is Associated with Severity of COVID-19 in Patients with Comorbidities
Background: There is a limited understanding of molecular and cellular events that derive disease progression in patients with corona virus disease 2019 (COVID-19). Receptor for advanced glycation end products (RAGE) is hyperactive in development and complications of several diseases by mediating oxidative stress and inflammation in the body. The present study aims to explore activation of RAGE signaling in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with preexisting comorbidities, including hypertension and or diabetes. Methods: A total of 442 subjects with COVID-19, were recruited for the study. The molecular mechanism of Covid-19 was explored in blood cells, using ELISA, RT- PCR and Western blot. Results: Enhanced levels of ligands of RAGE, including AGEs, S100, and high-mobility group box-1 (HMGB-1) were observed in COVID-19 patients with severe diseases; however, their level was significantly higher in COVID-19 patients with comorbidities compared to COVID-19 patients without comorbidities. The expression of RAGE in parallel to ligands accumulation was significantly increased in patients with severe disease and comorbidities compared to COVID-19 patients with severe disease without comorbidities. The expression of downstream effectors of RAGE, including STAT-3 and nuclear factor kappa B (NF-kB), was also enhanced and their activity was increased in COVID-19 patients with comorbidities. Levels of inflammatory and oxidative stress biomarkers were markedly increased in COVID-19 patients with comorbidities. Conclusions: We conclude that upregulated RAGE axis plays critical role, to worsen the severity of the SARS-CoV-2 infection in patients with preexisting comorbidities and partly explain inflammatory and oxidative stress storm in severe COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Metabolic syndrome and related disorders - 21(2023), 3 vom: 08. Apr., Seite 141-147 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Waraich, Rizwana Sanaullah [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.04.2023 Date Revised 08.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/met.2022.0089 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352940689 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352940689 | ||
| 003 | DE-627 | ||
| 005 | 20231226054850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/met.2022.0089 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM352940689 | ||
| 035 | |a (NLM)36787461 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Waraich, Rizwana Sanaullah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhanced Expression of RAGE AXIS Is Associated with Severity of COVID-19 in Patients with Comorbidities |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2023 | ||
| 500 | |a Date Revised 08.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: There is a limited understanding of molecular and cellular events that derive disease progression in patients with corona virus disease 2019 (COVID-19). Receptor for advanced glycation end products (RAGE) is hyperactive in development and complications of several diseases by mediating oxidative stress and inflammation in the body. The present study aims to explore activation of RAGE signaling in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with preexisting comorbidities, including hypertension and or diabetes. Methods: A total of 442 subjects with COVID-19, were recruited for the study. The molecular mechanism of Covid-19 was explored in blood cells, using ELISA, RT- PCR and Western blot. Results: Enhanced levels of ligands of RAGE, including AGEs, S100, and high-mobility group box-1 (HMGB-1) were observed in COVID-19 patients with severe diseases; however, their level was significantly higher in COVID-19 patients with comorbidities compared to COVID-19 patients without comorbidities. The expression of RAGE in parallel to ligands accumulation was significantly increased in patients with severe disease and comorbidities compared to COVID-19 patients with severe disease without comorbidities. The expression of downstream effectors of RAGE, including STAT-3 and nuclear factor kappa B (NF-kB), was also enhanced and their activity was increased in COVID-19 patients with comorbidities. Levels of inflammatory and oxidative stress biomarkers were markedly increased in COVID-19 patients with comorbidities. Conclusions: We conclude that upregulated RAGE axis plays critical role, to worsen the severity of the SARS-CoV-2 infection in patients with preexisting comorbidities and partly explain inflammatory and oxidative stress storm in severe COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HMGB-1 | |
| 650 | 4 | |a NF-kB | |
| 650 | 4 | |a RAGE | |
| 650 | 4 | |a STAT-3 | |
| 650 | 4 | |a advance glycation end products | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a inflammation | |
| 650 | 7 | |a Receptor for Advanced Glycation End Products |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 700 | 1 | |a Sohail, Fadieleh Adnan |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Gulnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Durr-E-Shahwar, Syeda |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Bushra |e verfasserin |4 aut | |
| 700 | 1 | |a Rafi, Sidra |e verfasserin |4 aut | |
| 700 | 1 | |a Nasir, Shumaila |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Metabolic syndrome and related disorders |d 2003 |g 21(2023), 3 vom: 08. Apr., Seite 141-147 |w (DE-627)NLM175065497 |x 1557-8518 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:3 |g day:08 |g month:04 |g pages:141-147 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/met.2022.0089 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 3 |b 08 |c 04 |h 141-147 | ||